"What" Series

What is Triple-Negative Breast Cancer?

28 April 2024
2 min read

Triple-Negative Breast Cancer (TNBC) is a special type of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on the surface of cancer cells. Due to the negativity of these three important therapeutic targets, treatment options for TNBC are relatively limited, and patients typically cannot benefit from hormone therapy or HER2-targeted therapy.

TNBC accounts for 10% to 20.8% of all breast cancer pathological types and is characterized by high invasiveness, metastasis, and recurrence rates, leading to a relatively poor prognosis. Additionally, a higher proportion of TNBC patients harbor BRCA1 or BRCA2 gene mutations, which suggests a strong association between TNBC and hereditary breast cancer.

In terms of treatment, TNBC typically relies on chemotherapy. In recent years, some progress has been made in chemotherapy, targeted therapy, and immunotherapy, such as the application of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, bringing new hope for the treatment of TNBC patients. Furthermore, some novel drugs and treatment regimens, such as PARP inhibitors and Trop-2 targeted drugs, have also shown potential in the treatment of TNBC.

It is worth noting that the treatment strategies for TNBC are continuously evolving and optimizing, and patients' survival rates and quality of life have improved with the emergence of new therapies. However, due to the complexity and heterogeneity of this type of breast cancer, personalized treatment and precision medicine remain important directions for future research and treatment.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy
Latest Hotspot
2 min read
Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy
28 April 2024
Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
28 April 2024
April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Endeavor BioMedicines Secures $132.5M in Oversubscribed Series C to Advance Medical Pipeline
Latest Hotspot
3 min read
Endeavor BioMedicines Secures $132.5M in Oversubscribed Series C to Advance Medical Pipeline
28 April 2024
Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.
Read →
What clinical indicator is BCVA?
"What" Series
2 min read
What clinical indicator is BCVA?
28 April 2024
BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.